Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention

Danish Medical Bulletin

Volumn 58, Issue 5, 2011, Pages

  Kupisiewicz, Kasia ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; RESVERATROL; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; DLK1 PROTEIN, HUMAN; MEMBRANE PROTEIN; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE; SIGNAL PEPTIDE; STILBENE DERIVATIVE; WNT PROTEIN;

ARTICLE; BONE BIOPSY; BONE DESTRUCTION; BONE REMODELING; BONE STRUCTURE; DRUG MECHANISM; MULTIPLE MYELOMA; OSTEOLYSIS; BONE; HUMAN; OSTEOBLAST; OSTEOCLAST; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BONE AND BONES; BONE REMODELING; BONE RESORPTION; BORONIC ACIDS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; MULTIPLE MYELOMA; OSTEOBLASTS; OSTEOCLASTS; PROTEASE INHIBITORS; PYRAZINES; SIGNAL TRANSDUCTION; STILBENES; WNT PROTEINS;

EID: 79956110813     PISSN: 16039629     EISSN: 16039629     Source Type: Journal    
DOI: None     Document Type: Article

References (222)

1. Aarden EM, Burger EH, Nijweide PJ (1994) Function of osteocytes in bone. J.Cell Biochem. 55:287-299
2. Abdallah BM, Boissy P, Tan Q, Dahlgaard J, Traustadottir GA, Kupisiewicz K, Laborda J, Delaisse JM, Kassem M (2007) Dlk1/FA1 regulates the function of human bone marrow mesenchymal stem cells by modulating gene expression of proinflammatory cytokines and immune responserelated factors. J.Biol.Chem. 282:7339-7351
3. Abdallah BM, Jensen CH, Gutierrez G, Leslie RG, Jensen TG, Kassem M (2004) Regulation of human skeletal stem cells differentiation by Dlk1/Pref-1. J.Bone Miner.Res. 19:841-852
4. Abdallah BM, Jensen CH, Gutierrez G, Leslie RG, Jensen TG, Kassem M (2004) Regulation of human skeletal stem cells differentiation by Dlk1/Pref-1. J.Bone Miner.Res. 19:841-852
5. Abdallah BM, Kassem M (2008) Human mesenchymal stem cells: from basic biology to clinical applications. Gene Ther. 15:109-116
6. Abe M, Hiura K, Wilde J, Moriyama K, Hashimoto T, Ozaki S, Wakatsuki S, Kosaka M, Kido S, Inoue D, Matsumoto T (2002) Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood 100:2195-2202
7. Abe M, Hiura K, Wilde J, Shioyasono A, Moriyama K, Hashimoto T, Kido S, Oshima T, Shibata H, Ozaki S, Inoue D, Matsumoto T (2004) Osteoclasts enhance myeloma cell growth and survival via cellcell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 104:2484-2491
8. Abe M, Kido S, Hiasa M, Nakano A, Oda A, Amou H, Matsumoto T (2006) BAFF and APRIL as osteoclastderived survival factors for myeloma cells: a rationale for TACI-Fc treatment in patients with multiple myeloma. Leukemia 20:1313-1315
9. Abildgaard N, Rungby J, Glerup H, Brixen K, Kassem M, Brincker H, Heickendorff L, Eriksen EF, Nielsen JL (1998) Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma. Eur.J.Haematol. 61:128-134
10. Akhtari M, Mansuri J, Newman KA, Guise TM, Seth P (2008) Biology of breast cancer bone metastasis. Cancer Biol.Ther. 7:3-9
11. Andersen NF, Standal T, Nielsen JL, Heickendorff L, Borset M, Sorensen FB, Abildgaard N (2005) Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival. Br.J.Haematol. 128:210-217
12. Andersen TL, Boissy P, Sondergaard TE, Kupisiewicz K, Plesner T, Rasmussen T, Haaber J, Kolvraa S, Delaisse JM (2007) Osteoclast nuclei of myeloma patients show chromosome translocations specific for the myeloma cell clone: a new type of cancerhost partnership? J.Pathol. 211:10-17
13. Andersen TL, Sondergaard TE, Skorzynska KE, Gnaes-Hansen F, Plesner TL, Hauge EM, Plesner T, Delaisse JM (2009) A physical mechanism for coupling bone resorption and formation in adult human bone. Am.J.Pathol. 174:239-247
14. Anderson K (1999) Advances in the biology of multiple myeloma: therapeutic applications. Semin.Oncol. 26:10-22
15. Anderson KC (2005) Lenalidomide and thalidomide: mechanisms of action--similarities and differences. Semin.Hematol. 42:S3-S8
16. Anderson KC, Prince HM (2005) Lenalidomide and thalidomide: an evolving paradigm for the management of multiple myeloma. Semin.Hematol. 42:S1-S2
17. Aparicio A, Gardner A, Tu Y, Savage A, Berenson J, Lichtenstein A (1998) In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 12:220-229
18. Arnett TR, Gibbons DC, Utting JC, Orriss IR, Hoebertz A, Rosendaal M, Meghji S (2003) Hypoxia is a major stimulator of osteoclast formation and bone resorption. J.Cell Physiol 196:2-8
19. Asagiri M, Takayanagi H (2007) The molecular understanding of osteoclast differentiation. Bone 40:251-264
20. Ashikawa K, Majumdar S, Banerjee S, Bharti AC, Shishodia S, Aggarwal BB (2002) Piceatannol inhibits TNF-induced NF-kappaB activation and NFkappaB-mediated gene expression through suppression of IkappaBalpha kinase and p65 phosphorylation. J.Immunol. 169:6490-6497
21. Baatout S, Derradji H, Jacquet P, Ooms D, Michaux A, Mergeay M (2004) Enhanced radiation-induced apoptosis of cancer cell lines after treatment with resveratrol. Int.J.Mol.Med. 13:895-902
22. Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, Fenton R, Gahres N, Sausville E, Ord R, Meiller T (2006) Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J.Clin.Oncol. 24:945-952
23. Banerjee S, Bueso-Ramos C, Aggarwal BB (2002) Suppression of 7,12-dimethylbenz(a)anthraceneinduced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res. 62:4945-4954
24. Bashir T, Pagano M (2003) Aberrant ubiquitinmediated proteolysis of cell cycle regulatory proteins and oncogenesis. Adv.Cancer Res. 88:101-144
25. Bataille R, Chappard D, Marcelli C, Dessauw P, Baldet P, Sany J, Alexandre C (1991) Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J.Clin.Invest 88:62-66
26. Baughn LB, Di LM, Wu K, Toogood PL, Louie T, Gottschalk R, Niesvizky R, Cho H, Ely S, Moore MA, Chen-Kiang S (2006) A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res. 66:7661-7667
27. Baumann P, Hagemeier H, Mandl-Weber S, Franke D, Schmidmaier R (2009) Myeloma cell growth inhibition is augmented by synchronous inhibition of the insulin-like growth factor-1 receptor by NVP-AEW541 and inhibition of mammalian target of rapamycin by Rad001. Anticancer Drugs 20:259-266
28. Bellamy WT (2001) Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies. Semin.Oncol. 28:551-559
29. Beyer M, Kochanek M, Giese T, Endl E, Weihrauch MR, Knolle PA, Classen S, Schultze JL (2006) In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. Blood 107:3940-3949
30. Bhardwaj A, Sethi G, Vadhan-Raj S, Bueso-Ramos C, Takada Y, Gaur U, Nair AS, Shishodia S, Aggarwal BB (2007) Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood 109:2293-2302
31. Bodine PV, Zhao W, Kharode YP, Bex FJ, Lambert AJ, Goad MB, Gaur T, Stein GS, Lian JB, Komm BS (2004) The Wnt antagonist secreted frizzledrelated protein-1 is a negative regulator of trabecular bone formation in adult mice. Mol.Endocrinol. 18:1222-1237
32. Body JJ, Facon T, Coleman RE, Lipton A, Geurs F, Fan M, Holloway D, Peterson MC, Bekker PJ (2006) A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin.Cancer Res. 12:1221-1228
33. Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Fermand JP, Harousseau JL, Lipton A, Mariette X, Williams CD, Nakanishi A, Holloway D, Martin SW, Dunstan CR, Bekker PJ (2003) A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97:887-892
34. Boissy P, Andersen TL, Abdallah BM, Kassem M, Plesner T, Delaisse JM (2005) Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation. Cancer Res. 65:9943-9952
35. Boissy P, Andersen TL, Lund T, Kupisiewicz K, Plesner T, Delaisse JM (2008) Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions. Leuk.Res. 32:1661-1668
36. Bollerslev J (1989) Autosomal dominant osteopetrosis: bone metabolism and epidemiological, clinical, and hormonal aspects. Endocr.Rev. 10:45-67
37. Bollerslev J, Steiniche T, Melsen F, Mosekilde L (1989) Structural and histomorphometric studies of iliac crest trabecular and cortical bone in autosomal dominant osteopetrosis: a study of two radiological types. Bone 10:19-24
38. Bonewald LF (2007) Osteocytes as dynamic multifunctional cells. Ann.N.Y.Acad.Sci. 1116:281-290
39. Bonewald LF, Johnson ML (2008) Osteocytes, mechanosensing and Wnt signaling. Bone 42:606-615
40. Boyce BF, Xing L (2007) Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res.Ther. 9 Suppl 1:S1
41. Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu D, Insogna K, Lifton RP (2002) High bone density due to a mutation in LDLreceptor-related protein 5. N.Engl.J.Med. 346:1513-1521
42. Boye J, Elter T, Engert A (2003) An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann.Oncol. 14:520-535
43. Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337-342
44. Breitkreutz I, Raab MS, Vallet S, Hideshima T, Raje N, Mitsiades C, Chauhan D, Okawa Y, Munshi NC, Richardson PG, Anderson KC (2008) Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 22:1925-1932
45. Brown RD, Pope B, Murray A, Esdale W, Sze DM, Gibson J, Ho PJ, Hart D, Joshua D (2001) Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to upregulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood 98:2992-2998
46. Bruder SP, Caplan AI (1989) Cellular and molecular events during embryonic bone development. Connect.Tissue Res. 20:65-71
47. Calvani N, Cafforio P, Silvestris F, Dammacco F (2005) Functional osteoclast-like transformation of cultured human myeloma cell lines. Br.J.Haematol. 130:926-938
48. Calvani N, Silvestris F, Cafforio P, Dammacco F (2004) Osteoclast-like cell formation by circulating myeloma B lymphocytes: Role of RANK-L. Leukemia & Lymphoma 45:377-380
49. Charles P, Eriksen EF, Mosekilde L, Melsen F, Jensen FT (1987) Bone turnover and balance evaluated by a combined calcium balance and 47calcium kinetic study and dynamic histomorphometry. Metabolism 36:1118-1124
50. Chauhan D, Singh A, Brahmandam M, Podar K, Hideshima T, Richardson P, Munshi N, Palladino MA, Anderson KC (2008) Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood 111:1654-1664
51. Chen Y, Tseng SH, Lai HS, Chen WJ (2004) Resveratrol-induced cellular apoptosis and cell cycle arrest in neuroblastoma cells and antitumor effects on neuroblastoma in mice. Surgery 136:57-66
52. Cho SW, Yang JY, Sun HJ, Jung JY, Her SJ, Cho HY, Choi HJ, Kim SW, Kim SY, Shin CS (2009) Wnt inhibitory factor (WIF)-1 inhibits osteoblastic differentiation in mouse embryonic mesenchymal cells. Bone 44:1069-1077
53. Choi SJ, Cruz JC, Craig F, Chung H, Devlin RD, Roodman GD, Alsina M (2000) Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 96:671-675
54. Clines GA, Guise TA (2004) Mechanisms and treatment for bone metastases. Clin.Adv.Hematol.Oncol. 2:295-302
55. Costes V, Portier M, Lu ZY, Rossi JF, Bataille R, Klein B (1998) Interleukin-1 in multiple myeloma: producer cells and their role in the control of IL-6 production. Br.J.Haematol. 103:1152-1160
56. Cozzolino F, Torcia M, Aldinucci D, Rubartelli A, Miliani A, Shaw AR, Lansdorp PM, Di GR (1989) Production of interleukin-1 by bone marrow myeloma cells. Blood 74:380-387
57. Crowell JA, Korytko PJ, Morrissey RL, Booth TD, Levine BS (2004) Resveratrol-associated renal toxicity. Toxicol.Sci. 82:614-619
58. Cruz JC, Alsina M, Craig F, Yoneda T, Anderson JL, Dallas M, Roodman GD (2001) Ibandronate decreases bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma. Exp.Hematol. 29:441-447
59. David E, Sinha R, Chen J, Sun SY, Kaufman JL, Lonial S (2008) Perifosine synergistically enhances TRAILinduced myeloma cell apoptosis via up-regulation of death receptors. Clin.Cancer Res. 14:5090-5098
60. De La MJ, Uy HL, Guise TA, Story B, Boyce BF, Mundy GR, Roodman GD (1995) Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo. J.Clin.Invest 95:2846-2852
61. de Vernejoul MC (1989) Bone remodelling in osteoporosis. Clin.Rheumatol. 8 Suppl 2:13-15
62. Dhodapkar MV, Geller MD, Chang DH, Shimizu K, Fujii S, Dhodapkar KM, Krasovsky J (2003) A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J.Exp.Med. 197:1667-1676
63. Dong Z (2003) Molecular mechanism of the chemopreventive effect of resveratrol. Mutat.Res. 523-524:145-150
64. Erlichman C (2009) Tanespimycin: the opportunities and challenges of targeting heat shock protein 90. Expert.Opin.Investig.Drugs 18:861-868
65. Everts V, Delaisse JM, Korper W, Jansen DC, Tigchelaar-Gutter W, Saftig P, Beertsen W (2002) The bone lining cell: its role in cleaning Howship's lacunae and initiating bone formation. J.Bone Miner.Res. 17:77-90
66. Franz-Odendaal TA, Hall BK, Witten PE (2006) Buried alive: how osteoblasts become osteocytes. Dev.Dyn. 235:176-190
67. Frost P, Moatamed F, Hoang B, Shi Y, Gera J, Yan H, Frost P, Gibbons J, Lichtenstein A (2004) In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood 104:4181-4187
68. Fukushima O, Bekker PJ, Gay CV (1991) Characterization of the functional stages of osteoclasts by enzyme histochemistry and electron microscopy. Anat.Rec. 231:298-315
69. Gajate C, Mollinedo F (2007) Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood 109:711-719
70. Gaur T, Lengner CJ, Hovhannisyan H, Bhat RA, Bodine PV, Komm BS, Javed A, van Wijnen AJ, Stein JL, Stein GS, Lian JB (2005) Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J.Biol.Chem. 280:33132-33140
71. Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S (2001) Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 98:3527-3533
72. Giuliani N, Colla S, Morandi F, Lazzaretti M, Sala R, Bonomini S, Grano M, Colucci S, Svaldi M, Rizzoli V (2005) Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 106:2472-2483
73. Giuliani N, Morandi F, Tagliaferri S, Lazzaretti M, Bonomini S, Crugnola M, Mancini C, Martella E, Ferrari L, Tabilio A, Rizzoli V (2007) The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 110:334-338
74. Giuliani N, Rizzoli V, Roodman GD (2006) Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition. Blood 108:3992-3996
75. Goel A, Dispenzieri A, Greipp PR, Witzig TE, Mesa RA, Russell SJ (2005) PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis. Exp.Hematol. 33:784-795
76. Gordon S, Helfrich MH, Sati HI, Greaves M, Ralston SH, Culligan DJ, Soutar RL, Rogers MJ (2002) Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma. Br.J.Haematol. 119:475-483
77. Greenstein S, Ghias K, Krett NL, Rosen ST (2002) Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies. Clin.Cancer Res. 8:1681-1694
78. Gu G, Mulari M, Peng Z, Hentunen TA, Vaananen HK (2005) Death of osteocytes turns off the inhibition of osteoclasts and triggers local bone resorption. Biochem.Biophys.Res.Commun. 335:1095-1101
79. Gu X, Creasy L, Kester A, Zeece M (1999) Capillary electrophoretic determination of resveratrol in wines. J.Agric.Food Chem. 47:3223-3227
80. Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12:9-22
81. Hadjidakis DJ, Androulakis II (2006) Bone remodeling. Ann.N.Y.Acad.Sci. 1092:385-396
82. Halvorsen YD, Franklin D, Bond AL, Hitt DC, Auchter C, Boskey AL, Paschalis EP, Wilkison WO, Gimble JM (2001) Extracellular matrix mineralization and osteoblast gene expression by human adipose tissue-derived stromal cells. Tissue Eng 7:729-741
83. Han JH, Choi SJ, Kurihara N, Koide M, Oba Y, Roodman GD (2001) Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood 97:3349-3353
84. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70
85. Hauge EM, Qvesel D, Eriksen EF, Mosekilde L, Melsen F (2001) Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers. J.Bone Miner.Res. 16:1575-1582
86. Hecht M, von M, I, Sack K, Kaiser M, Sezer O (2008) Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA). Exp.Cell Res. 314:1082-1093
87. Heider U, Kaiser M, Muller C, Jakob C, Zavrski I, Schulz CO, Fleissner C, Hecht M, Sezer O (2006) Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Eur.J.Haematol. 77:233-238
88. Henriksen K, Sorensen MG, Jensen VK, Dziegiel MH, Nosjean O, Karsdal MA (2008) Ion transporters involved in acidification of the resorption lacuna in osteoclasts. Calcif.Tissue Int.83:230-242
89. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, Adams J, Anderson KC (2002) NF-kappa B as a therapeutic target in multiple myeloma. J.Biol.Chem. 277:16639-16647
90. Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K, Mitsiades C, Munshi NC, Richardson PG, Carrasco RD, Anderson KC (2009) Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 114:1046-1052
91. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61:3071-3076
92. Hjertner O, Torgersen ML, Seidel C, Hjorth-Hansen H, Waage A, Borset M, Sundan A (1999) Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: a possible role for HGF in myeloma-associated osteolytic bone disease. Blood 94:3883-3888
93. Hongming H, Jian H (2009) Bortezomib inhibits maturation and function of osteoclasts from PBMCs of patients with multiple myeloma by downregulating TRAF6. Leuk.Res. 33:115-122
94. Hu Y, Sun CY, Huang J, Hong L, Zhang L, Chu ZB (2007) Antimyeloma effects of resveratrol through inhibition of angiogenesis. Chin Med.J.(Engl.) 120:1672-1677
95. Ikezoe T, Nishioka C, Tasaka T, Yang Y, Komatsu N, Togitani K, Koeffler HP, Taguchi H (2006) The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling. Mol.Cancer Ther. 5:2522-2530
96. Itonaga I, Sabokbar A, Sun SG, Kudo O, Danks L, Ferguson D, Fujikawa Y, Athanasou NA (2004) Transforming growth factor-beta induces osteoclast formation in the absence of RANKL. Bone 34:57-64
97. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, Pezzuto JM (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275:218-220
98. Jazirehi AR, Bonavida B (2004) Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxelinduced apoptosis. Mol.Cancer Ther. 3:71-84
99. Jia D, O'Brien CA, Stewart SA, Manolagas SC, Weinstein RS (2006) Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology 147:5592-5599
100. Johnson RA, Boyce BF, Mundy GR, Roodman GD (1989) Tumors producing human tumor necrosis factor induced hypercalcemia and osteoclastic bone resorption in nude mice. Endocrinology 124:1424-1427
101. Juarez JC, Betancourt O, Jr., Pirie-Shepherd SR, Guan X, Price ML, Shaw DE, Mazar AP, Donate F (2006) Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin.Cancer Res. 12:4974-4982
102. Jurdic P, Saltel F, Chabadel A, Destaing O (2006) Podosome and sealing zone: specificity of the osteoclast model. Eur.J.Cell Biol. 85:195-202
103. Justesen J, Pedersen SB, Stenderup K, Kassem M (2004) Subcutaneous adipocytes can differentiate into bone-forming cells in vitro and in vivo. Tissue Eng 10:381-391
104. Kanakis I, Kousidou OC, Karamanos NK (2005) In vitro and in vivo antiresorptive effects of bisphosphonates in metastatic bone disease. In Vivo 19:311-318
105. Kapoor P, Greipp PT, Morice WG, Rajkumar SV, Witzig TE, Greipp PR (2008) Anti-CD20 monoclonal antibody therapy in multiple myeloma. Br.J.Haematol. 141:135-148
106. Kim HJ, Zhao H, Kitaura H, Bhattacharyya S, Brewer JA, Muglia LJ, Patrick RF, Teitelbaum SL (2007) Glucocorticoids and the osteoclast. Ann.N.Y.Acad.Sci. 1116:335-339
107. Kim HJ, Zhao H, Kitaura H, Bhattacharyya S, Brewer JA, Muglia LJ, Ross FP, Teitelbaum SL (2007) Dexamethsone suppresses bone formation via the osteoclast. Adv.Exp.Med.Biol. 602:43-46
108. Kimura Y, Okuda H (2001) Resveratrol isolated from Polygonum cuspidatum root prevents tumor growth and metastasis to lung and tumor-induced neovascularization in Lewis lung carcinomabearing mice. J.Nutr. 131:1844-1849
109. Klein B, Tarte K, Jourdan M, Mathouk K, Moreaux J, Jourdan E, Legouffe E, De VJ, Rossi JF (2003) Survival and proliferation factors of normal and malignant plasma cells. Int.J.Hematol. 78:106-113
110. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao YH, Inada M, Sato M, Okamoto R, Kitamura Y, Yoshiki S, Kishimoto T (1997) Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89:755-764
111. Kondo T, Kitazawa R, Yamaguchi A, Kitazawa S (2008) Dexamethasone promotes osteoclastogenesis by inhibiting osteoprotegerin through multiple levels. J.Cell Biochem. 103:335-345
112. Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo SD, Bennett MK, van Leeuwen FW, Chanan-Khan AA, Orlowski RZ (2007) Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 110:3281-3290
113. Kuhnle G, Spencer JP, Chowrimootoo G, Schroeter H, Debnam ES, Srai SK, Rice-Evans C, Hahn U (2000) Resveratrol is absorbed in the small intestine as resveratrol glucuronide. Biochem.Biophys.Res.Commun. 272:212-217
114. Kukita T, Nomiyama H, Ohmoto Y, Kukita A, Shuto T, Hotokebuchi T, Sugioka Y, Miura R, Iijima T (1997) Macrophage inflammatory protein-1 alpha (LD78) expressed in human bone marrow: its role in regulation of hematopoiesis and osteoclast recruitment. Lab Invest 76:399-406
115. Kumar S, Anderson KC (2005) Drug insight: thalidomide as a treatment for multiple myeloma. Nat.Clin.Pract.Oncol. 2:262-270
116. Laborda J (2000) The role of the epidermal growth factor-like protein dlk in cell differentiation. Histol.Histopathol. 15:119-129
117. Layfield R (2007) The molecular pathogenesis of Paget disease of bone. Expert.Rev.Mol.Med. 9:1-13
118. Lecka-Czernik B, Moerman EJ, Grant DF, Lehmann JM, Manolagas SC, Jilka RL (2002) Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 143:2376-2384
119. Lee M, Advani R (2009) Targeting CD40 in Waldenstrom's macroglobulinemia. Clin.Lymphoma Myeloma. 9:87-89
120. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D (2005) Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J.Biol.Chem. 280:19883-19887
121. Lichtenstein A, Berenson J, Norman D, Chang MP, Carlile A (1989) Production of cytokines by bone marrow cells obtained from patients with multiple myeloma. Blood 74:1266-1273
122. Lipton A, Small E, Saad F, Gleason D, Gordon D, Smith M, Rosen L, Kowalski MO, Reitsma D, Seaman J (2002) The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest 20 Suppl 2:45-54
123. Liu F, Kohlmeier S, Wang CY (2008) Wnt signaling and skeletal development. Cell Signal. 20:999-1009
124. Lust JA, Donovan KA (1999) The role of interleukin-1 beta in the pathogenesis of multiple myeloma. Hematol.Oncol.Clin.North Am. 13:1117-1125
125. Luu HH, Song WX, Luo X, Manning D, Luo J, Deng ZL, Sharff KA, Montag AG, Haydon RC, He TC (2007) Distinct roles of bone morphogenetic proteins in osteogenic differentiation of mesenchymal stem cells. J.Orthop.Res. 25:665-677
126. Mao B, Wu W, Davidson G, Marhold J, Li M, Mechler BM, Delius H, Hoppe D, Stannek P, Walter C, Glinka A, Niehrs C (2002) Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature 417:664-667
127. McBeath R, Pirone DM, Nelson CM, Bhadriraju K, Chen CS (2004) Cell shape, cytoskeletal tension, and RhoA regulate stem cell lineage commitment. Dev.Cell 6:483-495
128. McDonald DF, Schofield BH, Prezioso EM, Adams VL, Frondoza CA, Trivedi SM, Craig C, Humphrey RL (1983) Direct bone resorbing activity of murine myeloma cells. Cancer Lett. 19:119-124
129. Menu E, Garcia J, Huang X, Di LM, Toogood PL, Chen I, Vanderkerken K, Chen-Kiang S (2008) A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model. Cancer Res. 68:5519-5523
130. Mercadante S (2002) The use of bisphosphonates in the management of bone metastatic prostate cancer. Curr.Urol.Rep. 3:244-249
131. Miller CP, Ban K, Dujka ME, McConkey DJ, Munsell M, Palladino M, Chandra J (2007) NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood 110:267-277
132. Moreaux J, Legouffe E, Jourdan E, Quittet P, Reme T, Lugagne C, Moine P, Rossi JF, Klein B, Tarte K (2004) BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 103:3148-3157
133. Mulari MT, Qu Q, Harkonen PL, Vaananen HK (2004) Osteoblast-like cells complete osteoclastic bone resorption and form new mineralized bone matrix in vitro. Calcif.Tissue Int. 75:253-261
134. Mundy GR (1991) The effects of TGF-beta on bone. Ciba Found.Symp. 157:137-143
135. Mundy GR, Raisz LG, Cooper RA, Schechter GP, Salmon SE (1974) Evidence for the secretion of an osteoclast stimulating factor in myeloma. N.Engl.J.Med. 291:1041-1046
136. Munshi NC, Wilson C (2001) Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis. Semin.Oncol. 28:565-569
137. Murias M, Jager W, Handler N, Erker T, Horvath Z, Szekeres T, Nohl H, Gille L (2005) Antioxidant, prooxidant and cytotoxic activity of hydroxylated resveratrol analogues: structure-activity relationship. Biochem.Pharmacol. 69:903-912
138. Myeloma Trialists' Collaborative Group (1998) Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Journal of Clinical Oncology 16:3832-3842
139. Nakagawa M, Kaneda T, Arakawa T, Morita S, Sato T, Yomada T, Hanada K, Kumegawa M, Hakeda Y (2000) Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts. FEBS Lett. 473:161-164
140. Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, Behringer RR, de CB (2002) The novel zinc fingercontaining transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 108:17-29
141. Niida S, Kaku M, Amano H, Yoshida H, Kataoka H, Nishikawa S, Tanne K, Maeda N, Nishikawa S, Kodama H (1999) Vascular endothelial growth factor can substitute for macrophage colonystimulating factor in the support of osteoclastic bone resorption. J.Exp.Med. 190:293-298
142. O'Brien CA, Jia D, Plotkin LI, Bellido T, Powers CC, Stewart SA, Manolagas SC, Weinstein RS (2004) Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 145:1835-1841
143. Okawa Y, Hideshima T, Steed P, Vallet S, Hall S, Huang K, Rice J, Barabasz A, Foley B, Ikeda H, Raje N, Kiziltepe T, Yasui H, Enatsu S, Anderson KC (2009) SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK. Blood 113:846-855
144. Oshima T, Abe M, Asano J, Hara T, Kitazoe K, Sekimoto E, Tanaka Y, Shibata H, Hashimoto T, Ozaki S, Kido S, Inoue D, Matsumoto T (2005) Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 106:3160-3165
145. Oyajobi BO, Garrett IR, Gupta A, Flores A, Esparza J, Munoz S, Zhao M, Mundy GR (2007) Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease. Br.J.Haematol. 139:434-438
146. Parfitt AM (1977) The cellular basis of bone turnover and bone loss: a rebuttal of the osteocytic resorption--bone flow theory. Clin.Orthop.Relat Res.236-247
147. Paul SR, Bennett F, Calvetti JA, Kelleher K, Wood CR, O'Hara RM, Jr., Leary AC, Sibley B, Clark SC, Williams DA,. (1990) Molecular cloning of a Cdna encoding interleukin 11, a stromal cell-derived lymphopoietic and hematopoietic cytokine. Proc.Natl.Acad.Sci.U.S.A 87:7512-7516
148. Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, Colman N, Michaeli J, Epstein J, Choi Y (2001) Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc.Natl.Acad.Sci.U.S.A 98:11581-11586
149. Pennisi A, Li X, Ling W, Khan S, Zangari M, Yaccoby S (2009) The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. Am.J.Hematol. 84:6-14
150. Pervaiz S (2003) Resveratrol: from grapevines to mammalian biology. FASEB J. 17:1975-1985
151. Pfeilschifter J, Chenu C, Bird A, Mundy GR, Roodman GD (1989) Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclastlike cells in vitro. J.Bone Miner.Res. 4:113-118
152. Planken EV, Dijkstra NH, Willemze R, Kluin-Nelemans JC (1996) Proliferation of B cell malignancies in all stages of differentiation upon stimulation in the 'CD40 system'. Leukemia 10:488-493
153. Planken EV, Willemze R, Kluin-Nelemans JC (1996) The role of the CD40 antigen on malignant B cells. Leuk.Lymphoma 22:229-235
154. Pogoda P, Priemel M, Rueger JM, Amling M (2005) Bone remodeling: new aspects of a key process that controls skeletal maintenance and repair. Osteoporos.Int. 16 Suppl 2:S18-S24
155. Prabhala RH, Neri P, Bae JE, Tassone P, Shammas MA, Allam CK, Daley JF, Chauhan D, Blanchard E, Thatte HS, Anderson KC, Munshi NC (2006) Dysfunctional T regulatory cells in multiple myeloma. Blood 107:301-304
156. Qiu W, Andersen TE, Bollerslev J, Mandrup S, Abdallah BM, Kassem M (2007) Patients with high bone mass phenotype exhibit enhanced osteoblast differentiation and inhibition of adipogenesis of human mesenchymal stem cells. J.Bone Miner.Res. 22:1720-1731
157. Raisz LG (1999) Physiology and pathophysiology of bone remodeling. Clin.Chem. 45:1353-1358
158. Raje N, Kumar S, Hideshima T, Ishitsuka K, Chauhan D, Mitsiades C, Podar K, Le GS, Richardson P, Munshi NC, Stirling DI, Antin JH, Anderson KC (2004) Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood 104:4188-4193
159. Rajkumar SV, Mesa RA, Fonseca R, Schroeder G, Plevak MF, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Gertz MA, Kyle RA, Russell SJ, Greipp PR (2002) Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin.Cancer Res. 8:2210-2216
160. Reddy SV, Takahashi S, Dallas M, Williams RE, Neckers L, Roodman GD (1994) Interleukin-6 antisense deoxyoligonucleotides inhibit bone resorption by giant cells from human giant cell tumors of bone. J.Bone Miner.Res. 9:753-757
161. Rifas L (2007) The role of noggin in human mesenchymal stem cell differentiation. J.Cell Biochem. 100:824-834
162. Rousselle AV, Heymann D (2002) Osteoclastic acidification pathways during bone resorption. Bone 30:533-540
163. Saftig P, Hunziker E, Everts V, Jones S, Boyde A, Wehmeyer O, Suter A, von FK (2000) Functions of cathepsin K in bone resorption. Lessons from cathepsin K deficient mice. Adv.Exp.Med.Biol. 477:293-303
164. Salo J, Metsikko K, Palokangas H, Lehenkari P, Vaananen HK (1996) Bone-resorbing osteoclasts reveal a dynamic division of basal plasma membrane into two different domains. J.Cell Sci. 109 (Pt 2):301-307
165. Sasaki T, Debari K, Hasemi M (1993) Measurement of Howship's resorption lacunae by a scanning probe microscope system. J.Electron Microsc.(Tokyo) 42:356-359
166. Schneider Y, Duranton B, Gosse F, Schleiffer R, Seiler N, Raul F (2001) Resveratrol inhibits intestinal tumorigenesis and modulates hostdefense-related gene expression in an animal model of human familial adenomatous polyposis. Nutr.Cancer 39:102-107
167. Seidel C, Borset M, Hjorth-Hansen H, Sundan A, Waage A (1998) Role of hepatocyte growth factor and its receptor c-met in multiple myeloma. Med.Oncol. 15:145-153
168. Seidel C, Borset M, Turesson I, Abildgaard N, Sundan A, Waage A (1998) Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group. Blood 91:806-812
169. Semenov M, Tamai K, He X (2005) SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J.Biol.Chem. 280:26770-26775
170. Sezer O, Heider U, Jakob C, Eucker J, Possinger K (2002) Human bone marrow myeloma cells express RANKL. J.Clin.Oncol. 20:353-354
171. Sezer O, Heider U, Jakob C, Zavrski I, Eucker J, Possinger K, Sers C, Krenn V (2002) Immunocytochemistry reveals RANKL expression of myeloma cells. Blood 99:4646-4647
172. Shammas MA, Koley H, Bertheau RC, Neri P, Fulciniti M, Tassone P, Blotta S, Protopopov A, Mitsiades C, Batchu RB, Anderson KC, Chin A, Gryaznov S, Munshi NC (2008) Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo. Leukemia 22:1410-1418
173. Shipman CM, Rogers MJ, Apperley JF, Graham R, Russell G, Croucher PI (1998) Anti-tumour activity of bisphosphonates in human myeloma cells. Leuk.Lymphoma 32:129-138
174. Silver IA, Murrills RJ, Etherington DJ (1988) Microelectrode studies on the acid microenvironment beneath adherent macrophages and osteoclasts. Exp.Cell Res. 175:266-276
175. Skobe M, Rockwell P, Goldstein N, Vosseler S, Fusenig NE (1997) Halting angiogenesis suppresses carcinoma cell invasion. Nat.Med. 3:1222-1227
176. Smas CM, Sul HS (1993) Pref-1, a protein containing EGF-like repeats, inhibits adipocyte differentiation. Cell 73:725-734
177. Song L, Tuan RS (2004) Transdifferentiation potential of human mesenchymal stem cells derived from bone marrow. FASEB J. 18:980-982
178. Standal T, Abildgaard N, Fagerli UM, Stordal B, Hjertner O, Borset M, Sundan A (2007) HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood 109:3024-3030
179. Standal T, Seidel C, Hjertner O, Plesner T, Sanderson RD, Waage A, Borset M, Sundan A (2002) Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 100:3002-3007
180. Stein R, Mattes MJ, Cardillo TM, Hansen HJ, Chang CH, Burton J, Govindan S, Goldenberg DM (2007) CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clin.Cancer Res. 13:5556s-5563s
181. Steiniche T (1995) Bone histomorphometry in the pathophysiological evaluation of primary and secondary osteoporosis and various treatment modalities. APMIS Suppl 51:1-44
182. Strauss SJ, Higginbottom K, Juliger S, Maharaj L, Allen P, Schenkein D, Lister TA, Joel SP (2007) The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines. Cancer Res. 67:2783-2790
183. Sun C, Hu Y, Liu X, Wu T, Wang Y, He W, Wei W (2006) Resveratrol downregulates the constitutional activation of nuclear factor-kappaB in multiple myeloma cells, leading to suppression of proliferation and invasion, arrest of cell cycle, and induction of apoptosis. Cancer Genet.Cytogenet. 165:9-19
184. Sun CY, Hu Y, Guo T, Wang HF, Zhang XP, He WJ, Tan H (2006) Resveratrol as a novel agent for treatment of multiple myeloma with matrix metalloproteinase inhibitory activity. Acta Pharmacol.Sin. 27:1447-1452
185. Takuma A, Kaneda T, Sato T, Ninomiya S, Kumegawa M, Hakeda Y (2003) Dexamethasone enhances osteoclast formation synergistically with transforming growth factor-beta by stimulating the priming of osteoclast progenitors for differentiation into osteoclasts. J.Biol.Chem. 278:44667-44674
186. Tanaka Y, Abe M, Hiasa M, Oda A, Amou H, Nakano A, Takeuchi K, Kitazoe K, Kido S, Inoue D, Moriyama K, Hashimoto T, Ozaki S, Matsumoto T (2007) Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin. Clin.Cancer Res. 13:816-823
187. Tatsumi S, Ishii K, Amizuka N, Li M, Kobayashi T, Kohno K, Ito M, Takeshita S, Ikeda K (2007) Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab 5:464-475
188. Taube T, Beneton MN, McCloskey EV, Rogers S, Greaves M, Kanis JA (1992) Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur.J.Haematol. 49:192-198
189. Teitelbaum SL (2000) Bone resorption by osteoclasts. Science 289:1504-1508
190. Terpos E (2006) Biochemical markers of bone metabolism in multiple myeloma. Cancer Treat.Rev. 32 Suppl 1:15-19
191. Terpos E, Heath DJ, Rahemtulla A, Zervas K, Chantry A, Anagnostopoulos A, Pouli A, Katodritou E, Verrou E, Vervessou EC, Dimopoulos MA, Croucher PI (2006) Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br.J.Haematol. 135:688-692
192. Terpos E, Politou M, Szydlo R, Goldman JM, Apperley JF, Rahemtulla A (2003) Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma. Br.J.Haematol. 123:106-109
193. Tessitore L, Davit A, Sarotto I, Caderni G (2000) Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21(CIP) expression. Carcinogenesis 21:1619-1622
194. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD, Jr. (2003) The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N.Engl.J.Med. 349:2483-2494
195. Tinhofer I, Biedermann R, Krismer M, Crazzolara R, Greil R (2006) A role of TRAIL in killing osteoblasts by myeloma cells. FASEB J. 20:759-761
196. Trikha M, Corringham R, Klein B, Rossi JF (2003) Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin.Cancer Res. 9:4653-4665
197. Troen BR (2004) The role of cathepsin K in normal bone resorption. Drug News Perspect. 17:19-28
198. Urashima M, Ogata A, Chauhan D, Hatziyanni M, Vidriales MB, Dedera DA, Schlossman RL, Anderson KC (1996) Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells. Blood 87:1928-1938
199. Uy GL, Trivedi R, Peles S, Fisher NM, Zhang QJ, Tomasson MH, DiPersio JF, Vij R (2007) Bortezomib inhibits osteoclast activity in patients with multiple myeloma. Clin.Lymphoma Myeloma. 7:587-589
200. Vaananen HK, Horton M (1995) The osteoclast clear zone is a specialized cell-extracellular matrix adhesion structure. J.Cell Sci. 108 (Pt 8):2729-2732
201. Vaananen HK, Laitala-Leinonen T (2008) Osteoclast lineage and function. Arch.Biochem.Biophys. 473:132-138
202. Vaananen HK, Zhao H, Mulari M, Halleen JM (2000) The cell biology of osteoclast function. J.Cell Sci. 113 (Pt 3):377-381
203. Vacca A, Ribatti D, Presta M, Minischetti M, Iurlaro M, Ria R, Albini A, Bussolino F, Dammacco F (1999) Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 93:3064-3073
204. Vacca A, Ribatti D, Roccaro AM, Frigeri A, Dammacco F (2001) Bone marrow angiogenesis in patients with active multiple myeloma. Semin.Oncol. 28:543-550
205. Vacca A, Ribatti D, Roccaro AM, Ria R, Palermo L, Dammacco F (2001) Bone marrow angiogenesis and plasma cell angiogenic and invasive potential in patients with active multiple myeloma. Acta Haematol. 106:162-169
206. Valdemarsson S, Lindergard B, Tibblin S, Bergenfelz A (1998) Increased biochemical markers of bone formation and resorption in primary hyperparathyroidism with special reference to patients with mild disease. J.Intern.Med. 243:115-122
207. Valentin-Opran A, Charhon SA, Meunier PJ, Edouard CM, Arlot ME (1982) Quantitative histology of myeloma-induced bone changes. Br.J.Haematol. 52:601-610
208. van Bezooijen RL, ten DP, Papapoulos SE, Lowik CW (2005) SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev. 16:319-327
209. Vejlgaard T, Abildgaard N, Jans H, Nielsen JL, Heickendorff L (1997) Abnormal bone turnover in monoclonal gammopathy of undetermined significance: analyses of type I collagen telopeptide, osteocalcin, bone-specific alkaline phosphatase and propeptides of type I and type III procollagens. Eur.J.Haematol. 58:104-108
210. Voorhees PM, Chen Q, Kuhn DJ, Small GW, Hunsucker SA, Strader JS, Corringham RE, Zaki MH, Nemeth JA, Orlowski RZ (2007) Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Clin.Cancer Res. 13:6469-6478
211. Voorhees PM, Chen Q, Small GW, Kuhn DJ, Hunsucker SA, Nemeth JA, Orlowski RZ (2009) Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death. Br.J.Haematol. 145:481-490
212. Wada T, Nakashima T, Hiroshi N, Penninger JM (2006) RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol.Med. 12:17-25
213. Weinstein RS (2001) Glucocorticoid-induced osteoporosis. Rev.Endocr.Metab Disord. 2:65-73
214. Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, Epstein J (2002) Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br.J.Haematol. 116:278-290
215. Yaccoby S, Wezeman MJ, Henderson A, Cottler-Fox M, Yi Q, Barlogie B, Epstein J (2004) Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res. 64:2016-2023
216. Yu L, Sun ZJ, Wu SL, Pan CE (2003) Effect of resveratrol on cell cycle proteins in murine transplantable liver cancer. World J.Gastroenterol. 9:2341-2343
217. Zambonin ZA, Teti A, Primavera MV (1984) Resorption of vital or devitalized bone by isolated osteoclasts in vitro. The role of lining cells. Cell Tissue Res. 235:561-564
218. Zangari M, Esseltine D, Lee CK, Barlogie B, Elice F, Burns MJ, Kang SH, Yaccoby S, Najarian K, Richardson P, Sonneveld P, Tricot G (2005) Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br.J.Haematol. 131:71-73
219. Zannettino AC, Farrugia AN, Kortesidis A, Manavis J, To LB, Martin SK, Diamond P, Tamamura H, Lapidot T, Fujii N, Gronthos S (2005) Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res. 65:1700-1709
220. Zavrski I, Krebbel H, Wildemann B, Heider U, Kaiser M, Possinger K, Sezer O (2005) Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function. Biochem.Biophys.Res.Commun. 333:200-205
221. Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, Alfonso ZC, Fraser JK, Benhaim P, Hedrick MH (2002) Human adipose tissue is a source of multipotent stem cells. Mol.Biol.Cell 13:4279-4295
222. Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz HP, Hedrick MH (2001) Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 7:211-228